TW202233683A - 針對wnt受體ryk之抗體變異體 - Google Patents

針對wnt受體ryk之抗體變異體 Download PDF

Info

Publication number
TW202233683A
TW202233683A TW110141972A TW110141972A TW202233683A TW 202233683 A TW202233683 A TW 202233683A TW 110141972 A TW110141972 A TW 110141972A TW 110141972 A TW110141972 A TW 110141972A TW 202233683 A TW202233683 A TW 202233683A
Authority
TW
Taiwan
Prior art keywords
antibody
ryk
seq
amino acid
chain variable
Prior art date
Application number
TW110141972A
Other languages
English (en)
Chinese (zh)
Inventor
大衛 Ｎ 豪瑟
泰勒 Ｌ 坎珀特
孫邈
Original Assignee
美商維薩醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維薩醫療股份有限公司 filed Critical 美商維薩醫療股份有限公司
Publication of TW202233683A publication Critical patent/TW202233683A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW110141972A 2020-11-11 2021-11-11 針對wnt受體ryk之抗體變異體 TW202233683A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112616P 2020-11-11 2020-11-11
US63/112,616 2020-11-11

Publications (1)

Publication Number Publication Date
TW202233683A true TW202233683A (zh) 2022-09-01

Family

ID=81601681

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110141972A TW202233683A (zh) 2020-11-11 2021-11-11 針對wnt受體ryk之抗體變異體

Country Status (9)

Country Link
US (1) US20230416375A1 (https=)
EP (1) EP4244259A4 (https=)
JP (1) JP2023552919A (https=)
KR (1) KR20230107628A (https=)
CN (1) CN117295767A (https=)
AU (1) AU2021380681A1 (https=)
CA (1) CA3201419A1 (https=)
TW (1) TW202233683A (https=)
WO (1) WO2022103705A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172733A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100522242C (zh) * 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
US8236307B2 (en) * 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
EP3533803B1 (en) * 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9862776B2 (en) * 2013-04-03 2018-01-09 Peter Maccallum Cancer Institute Antibodies against human RYK and uses therefor
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
WO2017172733A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
AU2018224094B2 (en) * 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies

Also Published As

Publication number Publication date
AU2021380681A1 (en) 2023-06-15
KR20230107628A (ko) 2023-07-17
US20230416375A1 (en) 2023-12-28
EP4244259A1 (en) 2023-09-20
CA3201419A1 (en) 2022-05-19
JP2023552919A (ja) 2023-12-19
CN117295767A (zh) 2023-12-26
AU2021380681A9 (en) 2024-02-08
WO2022103705A1 (en) 2022-05-19
EP4244259A4 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
TWI770020B (zh) 人類化抗pacap 抗體及其用途
JP6352812B6 (ja) 抗ｃｘｃｒ３抗体
CN101939337B (zh) 抗trka抗体及其衍生物
WO2019238882A1 (en) Il-11 antibodies
CA3101401A1 (en) Il-11ra antibodies
WO2019080872A1 (zh) 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
KR102040235B1 (ko) RGMa 결합 단백질 및 그 사용
KR20180100305A (ko) 암 성장을 억제하는 결합 분자
WO2021031716A1 (zh) 抗pd-l1单域抗体
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
TW201702266A (zh) 抗ｐａｃａｐ抗體及其用途
TW201315741A (zh) 結合至包含β－ＫＬＯＴＨＯ及ＦＧＦ受體之複合物之人類抗原結合蛋白
KR20230140553A (ko) Tl1a를 표적으로 하는 염증성 질환의 치료를 위한 방법, 시스템, 및 키트
CN113544150A (zh) 眼部病症中wnt信号传导的调节
TW202000232A (zh) 用以治療或預防異位性骨化之醫藥組成物
KR20150134319A (ko) 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편
TW202233683A (zh) 針對wnt受體ryk之抗體變異體
CN119137152A (zh) 抗par2抗体
WO2026082710A1 (en) Small molecule-inducible recombinant receptors
TW202540203A (zh) 結合pdgf-b與pdgf-d的抗原結合分子及使用方法
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
HK40115111A (zh) 抗pilra抗体、其用途以及相关方法和试剂
EP4602068A1 (en) Anti-scd146 antibodies and uses thereof